The total size of TeraImmune’s facility is 10,390 sqft with a common office area, conference room, general laboratory, cell culture room, storage room, QC lab, and 4 GMP rooms. Now, TeraImmune has the capability to develop Treg therapies from the bench to the clinical grade on its own. The GMP units are capable of manufacturing 4-6 clinical Treg products per month, which can cover 2-3 different programs in the early clinical stages (Phase 1/2a) simultaneously.
